Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Yahoo! Finance
Statutory earnings fell substantially short of expectations, with revenues of UK£598k missing forecasts by 94%. Losses exploded, with a per-share loss of UK£0.34 some 355% below prior forecasts. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. Check out our latest analysis for Silence Therapeutics Taking into account the latest results, the consensus forecast from Silence Therapeutics' five analysts is for revenues of UK£22.5m in 2024. This reflects a substantial 26% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 59% to UK£0.35. Yet prior to the latest earnings, the analysts had been forecasting revenues of UK£27.2m and losses of UK£0.30 per share in
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting Revenue - TechnavioPR Newswire
- Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' [Seeking Alpha]Seeking Alpha
- Silence Therapeutics plc (NASDAQ: SLN) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- Silence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesBusiness Wire
SLN
Sec Filings
- 8/15/24 - Form 6-K
- 8/2/24 - Form SC
- 6/27/24 - Form 6-K
- SLN's page on the SEC website